zw251
·Code: ZW251
zw251: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Zymeworks Inc. (ZYME) | Phase 1 |
Clinical Trials (1)
A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors, Including Hepatocellular Carcinoma
Frequently asked questions
Who is developing zw251?
zw251 is being developed by Zymeworks Inc..
How many clinical trials involve zw251?
BioSniper tracks 1 clinical trial involving zw251.
Get deeper analysis on zw251
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis